Carlos Galamba
With more than 18 years of experience in the IVD sector, including hands-on work as a scientist in transfusion medicine and infectious disease diagnostics, and regulatory review experience at BSI, one of the EU's largest Notified Bodies, Carlos Galamba brings a uniquely integrated perspective to IVD regulatory strategy. Their work spans Class C/D IVDs, companion diagnostics, NGS-based assays, and software-based IVDs, with a current advisory role to the European Commission on regulatory matters. At MDx CRO, they lead regulatory strategy for complex IVD programs across EU IVDR, FDA, and global markets.
Latest Articles
Blog & Insights
The future of in vitro diagnostics
In this post we analyze how the future of in vitro diagnostics is being written at the intersection…
Last Updated: 2026-05-19
Read more
Case studies
IVDR Transition for Precision Medicine: How MDx CRO Enabled a Seamless Portfolio Upgrade
Last Updated: 2026-08-06
Read more
Blog & Insights
A CRO’s Guide to IVD Analytical Validation: Best Practices & Common Pitfalls
Last Updated: 2026-07-14
Read more
Blog & Insights
IVD News
EU Reference Laboratories under IVDR: What Class D Manufacturers Must Know
Last Updated: 2026-06-16
Read more
Blog & Insights
Blog & Insights
The Role of a IVDR Legal Representative in Clinical Performance Studies
Last Updated: 2026-06-16
Read more
IVD News
FDA Laboratory Developed Tests (LDTs) Regulation
The FDA Laboratory Developed Tests regulation marks a major shift in U.S. diagnostics oversight. The FDA’s proposed LDT…
Last Updated: 2026-01-20
Read more